WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 201891
CAS#: 227963-15-7 (free)
Description: MK-0429 is a potent and selective inhibitor of the αvβ3 integrin, which showed therapeutic effects on bone turnover disease in men with hormone-refractory prostate cancer (HRPC) and bone metastases. MK-0429 was safe and efficacious in significantly decreasing melanoma metastasis in the lungs. MK-0429 may be useful for the prevention of metastatic melanoma.
MedKoo Cat#: 201891
CAS#: 227963-15-7 (free)
Chemical Formula: C23H29N5O4
Exact Mass: 439.22195
Molecular Weight: 439.51
Elemental Analysis: C, 62.85; H, 6.65; N, 15.93; O, 14.56
MK-0429 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Related CAS #: 477841-10-4 (5 hydrate) 227963-15-7 (free) 477841-08-0 (2 hydrate) 477841-09-1 (4 hydrate) 1125471-59-1 (0.5 hydrate)
Synonym: MK-0429; MK 0429; MK0429; L-000845704; L 000845704; L000845704.
IUPAC/Chemical Name: (S)-3-(6-methoxypyridin-3-yl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid
InChi Key: HGFOOLONGOBCMP-IBGZPJMESA-N
InChi Code: InChI=1S/C23H29N5O4/c1-32-20-9-7-17(15-25-20)19(14-21(29)30)28-13-12-27(23(28)31)11-3-5-18-8-6-16-4-2-10-24-22(16)26-18/h6-9,15,19H,2-5,10-14H2,1H3,(H,24,26)(H,29,30)/t19-/m0/s1
SMILES Code: O=C(O)C[C@@H](C1=CC=C(OC)N=C1)N2CCN(CCCC3=NC4=C(CCCN4)C=C3)C2=O
The following data is based on the product molecular weight 439.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Pickarski M, Gleason A, Bednar B, Duong le T. Orally active αvβ3 integrin
inhibitor MK-0429 reduces melanoma metastasis. Oncol Rep. 2015 Jun;33(6):2737-45.
doi: 10.3892/or.2015.3910. Epub 2015 Apr 9. PubMed PMID: 25872534; PubMed Central
2: Rosenthal MA, Davidson P, Rolland F, Campone M, Xue L, Han TH, Mehta A, Berd
Y, He W, Lombardi A. Evaluation of the safety, pharmacokinetics and treatment
effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease
activity in men with hormone-refractory prostate cancer and bone metastases. Asia
Pac J Clin Oncol. 2010 Mar;6(1):42-8. doi: 10.1111/j.1743-7563.2009.01266.x.
PubMed PMID: 20398037.